Approximately 25% of drugs in clinical use are metabolized by CYP2D6. Polymorphisms of CYP2D6 have the ability to affect efficacy, adverse side effects, and drug-drug interactions. Some of these drugs, including the SSRIs, may act as inhibitors when co-administered with other CYP2D6 substrates to patients with a normal CYP2D6 phenotype. When administered to PMs, these drugs may not be effective due to limited metabolism, or when several drugs are administered at once, the risk for severe adverse events may increase due to slower metabolism.

View Drugs Metabolized by CYP2D6